Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The eagerly-anticipated, full results of the phase 3 SURPASS trials were shared at ADA 2021. Earlier this year, exciting early results from several trials of tirzepatide showed that the new drug can lead to a sizable A1C reduction, significant weight loss, and less hypoglycemia among people with type 2 diabetes. Tirzepatide combines two types of drugs into a once-weekly injectable medication. This new glucose-lowering combination therapy is called a "dual agonist" or a “dual GIP and GLP-1 receptor agonist” and is currently in development to help people manage type 2 diabetes and help provide more stability in terms of weight.
The SURPASS-1 trial investigated tirzepatide in 478 adults with type 2 diabetes who needed treatment beyond diet and exercise to manage their blood sugar levels. Participants were randomly assigned to a certain dose of tirzepatide (either 5 mg, 10 mg, and 15 mg) or to the placebo group. After 40 weeks, all doses of tirzepatide lowered participants’ A1C, fasting glucose levels, and bodyweight.
diatribe.org
The SURPASS-1 trial investigated tirzepatide in 478 adults with type 2 diabetes who needed treatment beyond diet and exercise to manage their blood sugar levels. Participants were randomly assigned to a certain dose of tirzepatide (either 5 mg, 10 mg, and 15 mg) or to the placebo group. After 40 weeks, all doses of tirzepatide lowered participants’ A1C, fasting glucose levels, and bodyweight.
Tirzepatide Dramatically Lowers Weight and A1C
Full results from the SURPASS trials on the drug tirzepatide shows that this new medication dramatically lowers A1C and weight and is incredibly effective in people with type 2 diabetes. Read the latest from four clinical trials.
